Research Topics
Genomes and Genes | Socrates E PapapoulosSummaryAffiliation: Leiden University Medical Center Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatmentA H van Lierop
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
J Clin Endocrinol Metab 97:E1953-7. 2012..Sclerostin is an osteocyte-produced negative regulator of bone formation, which is up-regulated by glucocorticoids in mice...- Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extensionSocrates Papapoulos
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 27:694-701. 2012..Five-year denosumab treatment of women with postmenopausal osteoporosis maintained BTM reduction and increased BMD, and was associated with low fracture rates and a favorable risk/benefit profile... 
Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosisSocrates Papapoulos
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
Nat Clin Pract Endocrinol Metab 4:514-23. 2008..However, the optimum duration of PTH administration, as well as the efficacy of such regimens in reducing the risk of fractures, remain to be determined...- Use of bisphosphonates in the management of postmenopausal osteoporosisSocrates E Papapoulos
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
Ann N Y Acad Sci 1218:15-32. 2011..Selection of bisphosphonates for the treatment of individuals should be based on a careful review of efficacy data, a risk profile of the bisphosphonate, and values and preferences of the patient... 
Who will benefit from antiresorptive treatment (bisphosphonates)?Socrates E Papapoulos
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Best Pract Res Clin Rheumatol 19:965-73. 2005..Such studies may help to formulate treatment recommendations according to the risk of the individual patient...- Bisphosphonate actions: physical chemistry revisitedSocrates E Papapoulos
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Bone 38:613-6. 2006 - Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal womenSocrates E Papapoulos
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Osteoporos Int 16:468-74. 2005..The overall reduction is consistent among different patient populations... - Acquired resistance to bisphosphonates in Paget's disease of boneSocrates E Papapoulos
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 21:P88-91. 2006 - Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronateS E Papapoulos
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Ann Rheum Dis 66:853-8. 2007..Prolongation of the drug-free interval beyond 2 weeks should be compensated by a dose higher than the cumulative daily dose... - Bisphosphonates: how do they work?Socrates E Papapoulos
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
Best Pract Res Clin Endocrinol Metab 22:831-47. 2008..Current studies address questions related primarily to the pharmacological properties of these compounds that are essential for their optimal clinical use, such as for example long-term safety and efficacy... - Targeting sclerostin as potential treatment of osteoporosisSocrates E Papapoulos
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Ann Rheum Dis 70:i119-22. 2011..In initial human studies, a single injection of the antibody to postmenopausal women increased serum P1NP and transiently decreased serum CTX. Clinical phase II studies with this antibody are currently underway... - Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancerJeroen T Buijs
Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
Cancer Res 67:8742-51. 2007..Because exogenous BMP7 can still counteract the breast cancer growth at the primary site and in bone, BMP7 may represent a novel therapeutic molecule for repression of local and bone metastatic growth of breast cancer... - Inhibition of bone resorption and growth of breast cancer in the bone microenvironmentJeroen T Buijs
Department of Endocrinology, Leiden University Medical Center, C4 R, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Bone 44:380-6. 2009..However, interference with the bone micro-environmental growth support could still be of therapeutic relevance when given to patients early in the course of bone metastatic disease... - Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastasesSerge C L M Cremers
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 20:1543-7. 2005..The apparent relationships between skeletal retention and antiresorptive effect could have implications for the design of optimal therapeutic regimens with BPs in patients with bone metastases from breast cancer... - Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnoverAntoon H van Lierop
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 26:2804-11. 2011..Further studies are needed to clarify the role of sclerostin on bone resorption... - Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnoverMaria P Yavropoulou
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
Bone 51:153-7. 2012..These increased levels may be due to a compensatory response to the increased number of osteoblasts at affected skeletal sites and may contribute to the increased bone resorption in patients with PC ... - Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extensionCaroline Brumsen
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
J Bone Miner Res 17:1057-64. 2002..One hundred fifty milligrams daily of pamidronate is an effective and safe treatment of women and men with established osteoporosis... - Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancerVidija Soerdjbalie-Maikoe
Department of Urology, Leiden University Medical Center, Leiden, The Netherlands
Eur J Nucl Med Mol Imaging 31:958-63. 2004..Our data suggest that there is still a place for bone scintigraphy in the management of hormone-refractory prostate cancer... - Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's diseaseSerge C L M Cremers
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
Osteoporos Int 16:1727-30. 2005..This adequacy is confirmed by appropriate suppression of bone resorption and increase in lumbar spine BMD. These data hold significant implications for the clinical management of patients with Crohn's disease and osteoporosis... - Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivoGabri van der Pluijm
Department of Endocrinology, Leiden University Medical Center, Leiden, Netherlands
Cancer Res 65:7682-90. 2005..Inhibition of bone turnover may represent a useful adjuvant therapy especially for cancer patients at risk to develop bone metastasis... - BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivoJeroen T Buijs
Department of Urology, Leiden University Medical Center, J3 100, P O Box 9600, 2300 RC Leiden, The Netherlands
Am J Pathol 171:1047-57. 2007..Thus, BMP7 can still counteract the epithelial-to-mesenchymal transition process in the metastatic tumor, positioning BMP7 as a novel therapeutic molecule for treatment of metastatic bone disease... - Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey--the Rotterdam StudyMarelise E M W Eekhoff
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 19:566-70. 2004..This study demonstrated that serum ALP activity is a sensitive marker of PDB in men and women >55 years of age, but the majority of those affected have normal serum ALP activity... - Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapyMarelise E M W Eekhoff
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
Bone 33:831-8. 2003..In addition, we identified and quantified determinants of the response to bisphosphonate that can help in improving the management of patients with Paget's disease with bisphosphonates... - Glucocorticoids are not always deleterious for boneAntoon H J M van Lierop
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 25:2796-800. 2010..The exact mechanism by which sclerostin may be involved in the regulation of bone resorption is as yet to be explored... - SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular developmentRutger L van Bezooijen
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
Dev Dyn 236:606-12. 2007..Activity of both signaling pathways was already down-regulated before induction of SOST expression... - Low-energy fractures of the humeral shaft and bisphosphonate useMaria P Yavropoulou
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 27:1425-31. 2012..Our results show that low-energy fractures of the humeral shaft with "atypical" radiographic characteristics are infrequent and are not associated with the use of bisphosphonates or glucocorticoids... - Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritisSerge C L M Cremers
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
J Rheumatol 31:1732-7. 2004..We investigated the whole body retention (WBR) of pamidronate and its relationship to bone resorption and cartilage degradation in patients with active RA... - Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and featuresAndrea Giusti
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
Bone 48:966-71. 2011..1% of all femoral fractures), compared to ordinary ST/FS fractures are more frequent in bisphosphonate users, but equally occur in patients never treated with bisphosphonates... - Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonistRutger L van Bezooijen
Department of Endocrinology, C4 R, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Netherlands
J Exp Med 199:805-14. 2004..Its unique localization and action on osteoblasts suggest that sclerostin may be the previously proposed osteocyte-derived factor that is transported to osteoblasts at the bone surface and inhibits bone formation... - SOST/sclerostin, an osteocyte-derived negative regulator of bone formationRutger L van Bezooijen
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Cytokine Growth Factor Rev 16:319-27. 2005..The exclusive bone phenotype of good quality of patients with sclerosteosis and Van Buchem disease and the specific localization of sclerostin make it an attractive target for the development of bone forming therapeutics... - Bisphosphonate therapy in children with secondary osteoporosisSocrates E Papapoulos
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
Horm Res Paediatr 76:24-7. 2011..Their use should be restricted to patients with fragility fractures and low bone mass... - Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studiesAndrea Giusti
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
Bone 47:169-80. 2010.... - Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in managementRob C M Pelger
Department of Urology, Leiden University Medical Center, The Netherlands
Bone 36:1-5. 2005..In this malignancy in which metastases have a predilection for bone, failure to recognize osteomalacia can only result in significantly increasing the burden of skeletal complications... - Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapyCaroline Brumsen
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
J Bone Miner Res 17:567-9. 2002 - Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of boneSerge C L M Cremers
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 18:868-75. 2003..Such approaches can lead to improved patient care and individualization of treatment of Paget's disease with bisphosphonates... - Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosisSerge C L M Cremers
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, The Netherlands
Clin Pharmacokinet 44:551-70. 2005..Recently, pharmacokinetic/pharmacodynamic models for response to bisphosphonates have been described and, at present, some of them are being used in the design of bisphosphonate regimens with long drug-free intervals... - Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formationRutger L van Bezooijen
Department of Endocrinology and Metabolic Diseases, Leiden Univerity Medical Center, Ther Netherlands
J Bone Miner Res 22:19-28. 2007..It inhibits BMP-stimulated bone formation both in vitro and in vivo but has no direct effect on BMP signaling. Instead, sclerostin inhibits Wnt signaling that is required for BMP-stimulated osteoblastic differentiation... - Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX genePolyzois Makras
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
J Clin Endocrinol Metab 93:1386-9. 2008..X-linked hypophosphatemic rickets (XLH) is characterized by hypophosphatemia and growth retardation. Early diagnosis and treatment improve growth... - Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriersAntoon H van Lierop
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
J Bone Miner Res 28:848-54. 2013..The small amounts of sclerostin produced by patients with VBD may explain their milder phenotype compared to that of patients with sclerosteosis, in whom serum sclerostin is undetectable... - Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?Janneke E Witteveen
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
Eur J Endocrinol 166:55-60. 2012..In patients with primary hyperparathyroidism (PHPT), data on the relationship between PTH and FGF23 are scarce and not always concordant... - Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor AMartine M L Deckers
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
Endocrinology 143:1545-53. 2002..In conclusion, VEGF-A produced by osteoblasts in response to BMPs is not involved in osteoblast differentiation, but couples angiogenesis to bone formation... - Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeletonVidya Soerdjbalie-Maikoe
Department of Urology, Leiden University Medical Center, Leiden, The Netherlands
Eur J Nucl Med Mol Imaging 29:494-8. 2002..The use of these agents opens new avenues in the difficult management of patients with advanced prostate cancer who are most at risk of developing SCC... - Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal miceMartine M L Deckers
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands
J Bone Miner Res 17:998-1007. 2002..On the other hand, our results confirm that bisphosphonates can be used safely in the treatment of disorders that affect the growing skeleton, such as in juvenile osteoporosis... - Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genisteinZhi-Chao Dang
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, The Netherlands
J Biol Chem 278:962-7. 2003..As a result, the balance between activated ERs and PPARgamma determines the biological effects of genistein on osteogenesis and adipogenesis. Our findings may explain distinct effects of genistein in different tissues... - Bone mineral density in sclerosteosis; affected individuals and gene carriersJessica C Gardner
Division of Human Genetics, Faculty of Health Sciences, University of Cape Town, South Africa
J Clin Endocrinol Metab 90:6392-5. 2005..In the present study we assessed the effect of variable expression of the genetic defect on bone mineral density (BMD) in patients and carriers of the determinant gene... - Sclerostin is a delayed secreted product of osteocytes that inhibits bone formationKenneth E S Poole
MRC Bone Research Group, Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
FASEB J 19:1842-4. 2005..In doing so, sclerostin may act as a key inhibitory signal governing skeletal microarchitecture... - Prolonged bisphosphonate release after treatment in childrenSocrates E Papapoulos
N Engl J Med 356:1075-6. 2007 - Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorptionJohn M Sanders
Department of Chemistry, 600 South Mathews Avenue, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
J Med Chem 48:2957-63. 2005..As such, they represent useful new leads for the discovery of new bone resorption, antiinfective and anticancer drugs...